Cited by 549Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

Open access

Navarese, Eliano P., Robinson, Jennifer G., Kowalewski, Mariusz, Kolodziejczak, Michalina, Andreotti, Felicita, Bliden, Kevin, Tantry, Udaya, Kubica, Jacek, Raggi, Paolo, Gurbel, Paul A.·2018·JAMA

DOI 10.1001/jama.2018.2525PMC PMC5933331

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials. Objective: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions. Data Sourcesand Study Selection: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies. Data Extraction and Synthesis: Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less potent, placebo, or control group). Main Outcomes and Measures: The coprimary end points were total mortality and cardiovascular mortality. Random-effects meta-regression and meta-analyses evaluated associations between baseline LDL-C level and reductions in mortality end points and secondary end points including major adverse cardiac events (MACE). Results: In 34 trials, 136 299 patients received more intensive and 133 989 received less intensive LDL-C lowering. All-cause mortality was lower for more vs less intensive therapy (7.08% vs 7.70%; rate ratio [RR], 0.92 [95% CI, 0.88 to 0.96]), but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with greater reductions in all-cause mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.91 [95% CI, 0.86 to 0.96]; P = .001; absolute risk difference [ARD], -1.05 incident cases per 1000 person-years [95% CI, -1.59 to -0.51]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Cardiovascular mortality was lower for more vs less intensive therapy (3.48% vs 4.07%; RR, 0.84 [95% CI, 0.79 to 0.89]) but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with a greater reduction in cardiovascular mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.86 [95% CI, 0.80 to 0.94]; P < .001; ARD, -1.0 incident cases per 1000 person-years [95% CI, -1.51 to -0.45]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Trials with baseline LDL-C levels of 160 mg/dL or greater had the greatest reduction in all-cause mortality (RR, 0.72 [95% CI, 0.62 to 0.84]; P < .001; 4.3 fewer deaths per 1000 person-years) in a meta-analysis. More intensive LDL-C lowering was also associated with progressively greater risk reductions with higher baseline LDL-C level for myocardial infarction, revascularization, and MACE. Conclusions and Relevance: In these meta-analyses and meta-regressions, more intensive compared with less intensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. This association was not present when baseline LDL-C level was less than 100 mg/dL, suggesting that the greatest benefit from LDL-C-lowering therapy may occur for patients with higher baseline LDL-C levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2018.2525

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674

Flagged first, then by citations

Show all 58 references

2 of the 58 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

TiceJA; Institute for Clincal and Economic Review (ICER). Evolocumab for treatment of high cholesterol: clinical effectiveness: new evidence update. Institute for Clincal and Economic Review website. https://icer-review.org/material/pcks9-inhibitors-neu/. June 13, 2017. Accessed March 16, 2018.

Sorted by citations

Items 301–400 of 549

Serum adiponectin level is positively associated with vascular reactivity index by digital thermal monitoring in patients with coronary artery disease
Hsiao, C.-H., Hsu, B., Lu, C., & Wang, J. (2023) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_30_23 · Cited by 6
Invasive coronary imaging of inflammation to further characterize high-risk lesions: what options do we have?
Los, J., Mensink, F. B., Mohammadnia, N., Opstal, T. S. J., Damman, P., Volleberg, R. H. J. A., Peeters, D. A. M., van Royen, N., García‐García, H. M., Cornel, J. H., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1352025 · Cited by 5
Perturbations in plasma amino acid and lipoprotein subfraction profiles in anorexia nervosa before and after refeeding: A metabolomic cross-sectional and longitudinal analysis
Perakakis, N., Funk, A. M., Kolb, T., Jonas, S., Hellerhoff, I., Tam, F. I., Bornstein, S. R., Chavakis, T., Mirtschink, P., & Ehrlich, S. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.01.014 · Cited by 5
National Trends in Statin Use in Lithuania from 2010 to 2021
Makarevičius, G., Rinkūnienė, E., & Badarienė, J. (2022) · Medicina · doi:10.3390/medicina59010037 · Cited by 5
Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy
Hyun, M. H., Lee, Y.-C., Choi, B. G., Na, J. O., Choi, C. U., Kim, J. W., Kim, E. J., Rha, S., Park, C. G., Lee, E. M., et al. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/3824823 · Cited by 6
The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes
Hyun, M. H., Jang, J. W., Choi, B. G., Na, J. O., Choi, C. U., Kim, J. W., Kim, E. J., Rha, S., Park, C. G., Lee, E. M., et al. (2019) · Medicine · doi:10.1097/md.0000000000018510 · Cited by 5
Effect of Low-Density Lipoprotein Cholesterol Goal Achievement on Vascular Physiology Evaluated by Quantitative Flow Ratio in Patients Who Underwent Percutaneous Coronary Intervention
Chen, L., Chen, Q., Zhong, J., Ye, Z., Ye, M., Yan, Y., Chen, L., & Luo, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.679599 · Cited by 5
Sustained low‐density lipoprotein‐cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting
Sánchez‐Bacaicoa, C., Galán, J., Guijarro, C., Rico‐Martín, S., Monréal, M., García, J. F. C., Aguilar‐Cortés, E., Muñoz-Torrero, J. F. S., & for FRENA Investigators (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13732 · Cited by 5
Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; a report from the CREDO-Kyoto registry
Kanenawa, K., Yamaji, K., Morimoto, T., Yamamoto, K., Domei, T., Hyodo, M., Shiomi, H., Furukawa, Y., Nakagawa, Y., Kadota, K., et al. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.05.011 · Cited by 4
Quantifying patient preferences about features of nonstatin lipid-lowering therapies: a discrete choice experiment in the United States
Reed, S. D., Sutphin, J., Gonzalez, J. M., Wallace, M. J., Stephenson, J. J., Electricwala, B., Bosworth, H. B., & Pagidipati, N. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011804 · Cited by 4
Calculated LDL-cholesterol: comparability of the extended Martin/Hopkins, Sampson/NIH, Friedewald and four other equations in South African patients
Carelse, A., Rossouw, H. M., Steyn, N., Martins, J., & Pillay, T. S. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208916 · Cited by 4
Optimization of the MACE endpoint composition to increase power in studies of lipid-lowering therapies—a model-based meta-analysis
Volkova, A., Shulgin, B., Helmlinger, G., Peskov, K. V., & Sokolov, V. V. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1242845 · Cited by 4
Efficacy and safety assessment of traditional Chinese patent medicine for dyslipidemia: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis
Fang, Y., Wu, H., Liang, X., Li, T., Jia, R., Dong, Y., Zheng, Y., Wang, Q., & Li, L. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-146 · Cited by 4
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease
Li, L., Huang, C., Liu, W., Li, J., Geru, A., Chen, X., Jiang, S., Fang, Y., Foo, R., Chan, M. Y., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.014 · Cited by 5
Impact of Onset-to-Needle Time on the Risk of Early Neurological Deterioration in Patients with Acute Ischemic Stroke Receiving Intravenous Thrombolysis
Hu, B., & Hua, J. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s515542 · Cited by 4
Statin Intolerance: An Overview for Clinicians
Surma, S., Lewek, J., Penson, P. E., & Banach, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_23 · Cited by 4
Anti-Obesity and Antidiabetic Effects of Fig (Ficus carica L.) Fermented Extract Using Lactobacillus plantarum BT-LP-01
Choi, H., Choi, J.-H., Jang, Y., Lee, Y., Kang, M.-H., Kwon, H.-S., Kim, S., & Kwon, J. (2024) · Applied Sciences · doi:10.3390/app14156412 · Cited by 7
Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
Liu, L., Deng, Y., Li, L., Yang, X., Yin, Z., & Lai, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310696 · Cited by 4
The quality, uniqueness, and causality of NMR-based prediction models for low-density lipoprotein cholesterol subfractions in human blood plasma
Ye, Y., Markussen, B., Engelsen, S. B., & Khakimov, B. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109379 · Cited by 5
Association of LDL ‐C/ HDL ‐C Ratio With Hyperuricemia: A National Cohort Study
Zhang, Y., Liu, X., Luo, D., Chen, B., Lai, C., He, C., Luo, Y., Ding, H., & Li, S. (2025) · Clinical and Translational Science · doi:10.1111/cts.70122 · Cited by 4
Low Cholesterol Levels in Younger Heart Failure Patients May Predict Unfavorable Outcomes
Charach, L., Grosskopf, I., Galin, L., Guterman, I., Karniel, E., & Charach, G. (2023) · Medicina · doi:10.3390/medicina59071314 · Cited by 4
Incremental Benefit of Lipid Lowering in a Large Chinese Population Aged 75 Years and Older With Established Atherosclerotic Cardiovascular Disease
Lin, Z., Chen, Y., Xiao, Z., Xu, W., Chen, G., Huang, C., Feng, W., Xie, Z., Liao, W., Liao, Y., et al. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.06.003 · Cited by 4
Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS
Jain, M., Sawant, R., Panchal, H., Anand, S. S., Jena, A. B., Gupta, R., Kumar, K., Jambunathan, R., Modi, S., Mullasari, A. S., et al. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200210 · Cited by 4
Effect of Speed Agility Quickness and Circuit Training on Lipid Profile of Soccer Players: An Observational Study
Farooque, S., Mitra, M., & Das, P. K. (2023) · Physical Education Theory and Methodology · doi:10.17309/tmfv.2023.6.12 · Cited by 4
Development, validation and visualization of a web-based nomogram for predicting risk of new-onset diabetes after percutaneous coronary intervention
Zhu, M., Li, Y. H., Wang, W., Liu, Y., Tong, T., & Liu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-64430-9 · Cited by 5
Overlapping Pattern of the Four Individual Components of Dyslipidemia in Adults: Analysis of Nationally Representative Data
Zheng, W., Zhang, J., Jiang, Y. H., Wang, S., & Yang, Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123624 · Cited by 4
Disentangling the inverse LDL-C-hemorrhagic stroke association in Chinese adults with hypertension: findings from the Chinese Multi-provincial Cohort Study
Yang, Z., Qi, Y., Sun, J., Liu, J., Wang, M., Deng, Q., Hao, Y., Yang, N., Ji, Z., Zhou, X., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae318 · Cited by 4
LDL-C Targets in Secondary Prevention: How Low Should We Go?
Bayoumy, K., Gaber, M., Mani, P., Puri, R., Donnellan, E., Cho, L., Clark, D., Martin, S. S., & Elshazly, M. B. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0619-8 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Long-Term Outcomes Following Coronary Revascularizations in Diabetes Mellitus
Navarese, E. P., Brouwer, M. A., & Kubica, J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.576 · Cited by 4
Self-citation
Hematological Effects and Benchmark Doses of Long-Term Co-Exposure to Benzene, Toluene, and Xylenes in a Follow-Up Study in Petrochemical WorkersPreprint
Zhang, Z., Liu, X., Guo, C., Zhang, X., Zhang, Y., Deng, N., Lai, G., Yang, A., Huang, Y., Dang, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4122079 · Cited by 4
Cholesterol Levels and Cardiovascular Outcomes Following Statin Initiation for Primary Prevention
Thompson, W., Jeong, I. J., Basque, S. R., Abdel-Qadir, H. M., Austin, P. C., Ko, D. T., Famiyeh, I., Chu, A., Fang, J., Odutayo, A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101864 · Cited by 3
LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis
Wang, Q., Liu, Z., Zhou, W., Wu, G., Hu, K., Su, H., Yan, J., & Chen, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-24832-9 · Cited by 4
Efficacy of Non-Invasive Ventilation in Acute Coronary Syndrome Patients with Acute Systolic Heart Failure
Qu, C., Zhao, Q., Cao, W., Dai, Z., Luo, X., & Zhang, R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2309294 · Cited by 3
Effectiveness of the low‐density lipoprotein cholesterol goals in secondary cardiovascular prevention
García-Gil, M., Alves‐Cabratosa, L., Cunillera, O., Blanch, J., Martí‐Lluch, R., Ponjoan, A., Ribas‐Aulinas, F., Tornabell‐Noguera, È., Zacarías‐Pons, L., Domínguez‐Armengol, G., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14258 · Cited by 3
Low-density lipoprotein cholesterol-to-lymphocyte count ratio (LLR) is a promising novel predictor of postoperative new-onset deep vein thrombosis following open wedge high tibial osteotomy: a propensity score-matched analysis
Guo, H., Li, C., Wu, H., Ma, M., Zhu, R., Wang, M., Yang, B., Pan, N., Zhu, Y., & Wang, J. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00635-2 · Cited by 3
Association of LDL-C with stroke and all-cause mortality in hypertensive patients with high risk of ASCVD
Guo, S., Wang, C., Hu, T., Lan, L., Ge, Z., Huang, J., Chen, S., Wu, S., & Xue, H. (2025) · Clinical Hypertension · doi:10.5646/ch.2025.31.e7 · Cited by 3
Differential lipid impact on mortality in patients undergoing CABG versus PCI
Yuan, X., Zhang, L., Li, X., Chen, K., Chu, Q., Chen, L., & Hu, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119141 · Cited by 3
Non high density lipoprotein to high density lipoprotein cholesterol ratio and type 2 diabetes in Middle aged and Elderly Chinese
Tan, J., Zhu, H., Zeng, Y., Li, J., Zhao, Y., Xiao, X., & Li, M. (2025) · Scientific Reports · doi:10.1038/s41598-024-84686-5 · Cited by 3
Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease: a two-year observational study
Mak, Y. H., Chua, F., Koh, X. H., Tan, V. H., Lee, Z. H., Lam, A., Tong, K. L., Yeo, C., Chow, W., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2024-172 · Cited by 3
Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels
Ma, H., Ma, W., Liu, Y., Chen, L., & Ding, P. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26980 · Cited by 3
Is Targeting LDL-C Levels Below 70 mg/dL Beneficial for Cardiovascular and Overall Health? A Critical Examination of the Evidence
van Bruggen, F. H., & Diamond, D. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103569 · Cited by 3
Physical activity dose-response and long-term effects on dyslipidemia in Chinese adults: a CHARLS study
Wan, K., Wang, R., Yan, H., Cheng, W., Ma, F., Jin, Y., & Wang, R. (2025) · BMC Public Health · doi:10.1186/s12889-025-24568-1 · Cited by 3
Intraoperative Lipoproteins Associated with Postoperative Delirium in a Prospective Observational Study of Older Adults Undergoing Cardiac Surgery
McKay, T. B., Graves, O. K., Mitchell, M., Mueller, A., Simon, C., Patel, P. H., Turco, I., Bertsch, J., Albanese, M. L., Gleeson, E., et al. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.09.235 · Cited by 3
Atherosclerosis of the Carotid Artery
Jansen, M. F., Lutgens, E., & Daemen, M. J. A. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-25249-6_4 · Cited by 3
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease
Expert group from the Spanish Arteriosclerosis Society, Pedro‐Botet, J., López‐Miranda, J., Badimón, L., Civeira, F., Guijarro, C., Millán, J., Mostaza, J. M., Pintó, X., Valdivielso, P., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00376-y · Cited by 3
Statin therapy and low-density lipoprotein cholesterol reduction after acute coronary syndrome: Insights from the United Arab Emirates
Shehab, A., & Bhagavathula, A. S. (2020) · Heart Views · doi:10.4103/heartviews.heartviews_115_19 · Cited by 3
Blood-Based and Imaging Biomarkers of Atherosclerosis
Ali, K., Lang, C. C., Huang, J. T. J., & Choy, A. M. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000442 · Cited by 3
Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
Citarella, A., Cammarota, S., Bernardi, F. F., Caliendo, L., D’Andrea, A., Fimiani, B., Fogliasecca, M., Pacella, D., Pagnotta, R., Trama, U., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154344 · Cited by 3
Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome
Augusto, C. T., Parada, M. D. L. P. S., Rossi, M. M., Signorini, F. J., Fonseca, I. B., & Báez, M. D. C. (2021) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523022666230223090714 · Cited by 3
The prognostic role of the low and very low baseline LDL-C level in outcomes of patients with cardiac revascularization; comparative registry-based cohort design
Rezaee, M., Fallahzadeh, A., Sheikhy, A., Ajam, A., Sadeghian, S., Bsc, M. P., Shirzad, M., Mansourian, S., Bagheri, J., & Hosseini, K. (2023) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-023-02333-y · Cited by 4
Association between low-density lipoprotein cholesterol level and all-cause mortality in idiopathic dilated cardiomyopathy patients: a single-institutional study
Jiang, K., Pu, X., Liu, Y., Xu, Y., Huang, F., & Chen, M. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2243127 · Cited by 3
Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis
Pamporis, K., Karakasis, P., Simantiris, S., Sagris, Μ., Bougioukas, K. I., Fragakis, N., & Tousoulis, D. M. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.11.003 · Cited by 3
Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy
Shi, L., Ye, Z., Gu, Q., & Li, Y. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.12.41 · Cited by 4
Association between blood lipids and diabetes mellitus in older Chinese adults aged 65 years or older: a cross-sectional analysis of residents’ electronic health records
Lin, T., Zhao, Y., Yang, Q., Wang, W., Jiang, X., & Qiu, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02160-7 · Cited by 3
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses
Johansson, K. S., Jimenez‐Solem, E., Petersen, T. S., & Christensen, M. (2024) · Diabetes Care · doi:10.2337/dc24-0619 · Cited by 4
A non-linear association of low-density lipoprotein cholesterol with all-cause and cardiovascular mortality among patients with hypertension
Liang, G., Ma, J., Zhang, W., Gu, X., Zhang, Q., Liu, A., & Qing, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1469848 · Cited by 3
Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort
Yu, X., Yuan, Y., Dong, X., Xier, Z., Ma, L., Peng, H., Li, G., & Yang, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2529565 · Cited by 3
Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
Werba, J. P., Vigo, L., Veglia, F., Marenzi, G., Tremoli, E., & Baldassarre, D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1436 · Cited by 3
Risk factors affecting the failed low‐density lipoprotein level achievement rate in working‐age male population at high cardiovascular risk
Momo, K., Yasu, T., Yasui, H., & Kuroda, S. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12847 · Cited by 3
Metabolic signatures of cholesterol biosynthesis and absorption in patients with coronary artery disease
Kwon, G. E., Hyun, M. H., Byun, D. J., Paeng, K., Seo, H. S., & Choi, M. H. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105940 · Cited by 3
Cholesterol transport in blood, lipoproteins, and cholesterol metabolism
Auley, M. T. M., & Morgan, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00025-0 · Cited by 3
L’hypertension artérielle en France, une situation préoccupante : une réplique du tremblement de terre cholestérol/statines ?
Blacher, J. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.05.011 · Cited by 3
Life‐Saving Medications: The Urgent Need for Guideline Adherence and Patient Acceptance
Braun, L. T. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012348 · Cited by 3
Lipid profiles and their association with incident carotid atherosclerosis: A community-based prospective study in Taiwan
Wu, T., Chou, C., Liu, C.-C., Chen, C.-F., Cheng, C.-F., & Wang, L. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104023 · Cited by 3
Electrocardiogram abnormalities and CVD mortality: prospective cohort study of Tehran lipid and glucose study
Mahmoodian, S., Khalili, D., Azizi, F., Haddizadeh, N., Nouri, B., & Aghaei, A. (2025) · BMC Public Health · doi:10.1186/s12889-025-23254-6 · Cited by 5
Low and Decreasing Cholesterol Levels and Risk of All-Cause and Cause-Specific Mortality: A Prospective and Longitudinal Cohort Study
Jiang, Q., Wu, J., Yu, Y., Hao, X., Long, P., Liu, K., Liu, S., Peng, R., Yu, K., Zeng, R., et al. (2025) · Engineering · doi:10.1016/j.eng.2025.06.032 · Cited by 2
Gypenosides Ameliorate Hyperlipidemia by Activating Lipophagy through Modulation of the AMPK/mTOR/ULK1 Signaling Pathway
Zhang, M., Jiang, Y., Lu, P., Shen, Z., Gao, X. Y., & Wang, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c11879 · Cited by 2
Frequency of low-density-lipoprotein-cholesterol measurement and risk of major adverse cardiovascular outcomes: a 5-million-person nationwide cohort study
Ngina, D. M., Doehner, W., Ntaios, G., Nartey, Y., & Akyea, R. K. (2025) · Global Cardiology · doi:10.4081/cardio.2025.85 · Cited by 2
Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study
Rai, H., Coughlan, J. J., O’Callaghan, D., Sheahan, R. G., Murphy, R. T., Burke, D., McFadden, E. P., Nolan, D., Colleran, R., Hazeez-Agbaje, A., et al. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04096-y · Cited by 2
Performance of Risk Score Calculators in the Identification of Coronary Artery Calcification in Patients With Systemic Lupus Erythematosus
Patel, H., Stoots, S. A., Feldt, J. V., & Baker, J. F. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-0465 · Cited by 2
Long-term outcomes according to absolute value vs. percentage reduction in low-density lipoprotein cholesterol levels after acute myocardial infarction
Cho, K. H., Yang, J. H., Lee, S. Y., Shin, M., Oh, S. K., Kim, M. C., Sim, D. S., Hong, Y. J., Kim, J. H., Ahn, Y., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1653447 · Cited by 2
Residual Cardiovascular Biomarkers After Medical Therapy and Their Prognostic Implications Following Percutaneous Coronary Intervention
Cho, J. H., Ahn, J., Kang, M. G., Bae, J. S., Koh, J.-S., Jung, M. K., Kim, S., Gorog, D. A., Tantry, U. S., Gurbel, P. A., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102498 · Cited by 2
Self-citation
Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy
Corsetti, G., & Pasini, E. (2026) · Nutrients · doi:10.3390/nu18050722 · Cited by 3
Mortality score in chronic coronary syndrome: prediction model from the ISCHEMIA trial
Navarese, E. P., Talanas, G., Kereiakes, D. J., Henry, T. D., Gąsior, M., Kalarus, Z. F., Umińska, J. M., Burzotta, F., Buffon, A., BELLE, E. V., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag116 · Cited by 2
Self-citation
Alpha-ketoglutarate accelerates granulocyte-monocyte progenitor differentiation and atherosclerotic plaque inflammation via oxoglutarate receptor 1
Zhao, J., Su, L., Li, W., Lam, S. M., Yan, C., Zhou, T., Deng, Y., Dong, Y., Zhou, Y., Shui, G., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104134 · Cited by 2
Effect of More Intensive LDL-C–Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Jin, S., Nie, X., Li, Y., Yuan, J., Cui, Y., & Zhao, L. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.019 · Cited by 2
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
Abdalwahab, A., Al‐Atta, A., Zaman, A., & Alkhalil, M. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.472 · Cited by 2
Higher serum triglyceride can predict recurrent coronary revascularization events in patients undergoing percutaneous coronary intervention with baseline LDL-C <55 mg/dL
Fan, X., Wang, X., She, J., Niu, X., Luo, Y., Wen, X., Zheng, T., & Wu, Y. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002401 · Cited by 2
Alterations of NMR-Based Lipoprotein Profile Distinguish Unstable Angina Patients with Different Severity of Coronary Lesions
Ye, Y., Fan, J., Chen, Z., Li, X., Wu, M., Liu, W., Zhou, S., Rasmussen, M. A., Engelsen, S. B., Chen, Y., et al. (2023) · Metabolites · doi:10.3390/metabo13020273 · Cited by 2
Low-density lipoprotein cholesterol to apolipoprotein B ratio predicts mortality and cardiovascular events in peritoneal dialysis patients
Zeng, C., Zhan, Q., Lv, L., Chen, Y., & Zhan, X. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03514-3 · Cited by 2
2023 Update in ambulatory general internal medicine
Alexander, J. T., Singh, S. K., Shah, S. D., Lambert, B., & Smith, J. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23056 · Cited by 2
Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat
Wang, H., Mao, Y.-C., Qi, S.-F., Xu, X., Zhang, Z., Geng, C., Song, K., & Tian, Q. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00651-7 · Cited by 2
Lipid-lowering therapies and long-term stroke prevention in East Asians: A systematic review and meta-analysis of randomized controlled trials
Guo, B., Li, H., Xu, P., & Zhao, B. (2024) · International Journal of Stroke · doi:10.1177/17474930241264686 · Cited by 2
Time course of remnant cholesterol and the risk of heart failure
Liu, X., Zhang, Y., Tian, X., Xu, Q., Xia, X., Chen, S., Liu, F., Wu, S., & Wang, A. (2024) · Endocrine · doi:10.1007/s12020-024-04028-3 · Cited by 2
Association Between Pericoronary Fat Attenuation Index as Evaluated by Coronary Artery CT Angiography and Clinical Interventions in Lipid Management Among Patients with Coronary Artery Disease
Feng, Y.-S., Sun, Z.-Y., Jiang, F., Ma, P., Liu, X.-R., Meng, Y., Liao, C., & Sun, G. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s468768 · Cited by 2
Protective effects of statins on pulmonary function in patients with persistent hyperlipidemia: a retrospective cohort study
Shen, H., Tseng, C.-H., Lin, Y.-H., Yeh, H., Tsai, H., Hong, S., Li, T., Su, C., Perng, D., Yang, Y., et al. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251320875 · Cited by 2
Determining cost-saving risk thresholds for statin use
Gandjour, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318454 · Cited by 2
Remnant cholesterol predicts risk of recurrent thrombosis beyond LDL-cholesterol in patients with antiphospholipid syndrome
Cai, B., Zhou, Y., Yang, X., Wang, Z., Huang, C. L., Xiao, Q., Jiang, H., Zhao, Y., Tian, X., Wang, Q., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04063-5 · Cited by 3
Shift in therapeutic approaches in patients with hypercholesterolemia - a secondary data analysis
Zink, E., Steinhäuser, J., Blickle, P.-G., von Meißner, W., & Strumann, C. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02982-z · Cited by 2
Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes
Giordano, S. A., Spadafora, L., Biondi‐Zoccai, G., & Bernardi, M. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001376 · Cited by 2
Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers
White, A. M. B., Mishcon, H. R., Redwanski, J. L., & Hills, R. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113748 · Cited by 2
Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
Ha, J., Lee, B., Park, J. M., Kang, M., Oh, J., Lee, C. J., Park, S., Kang, S., & Lee, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88416-z · Cited by 2
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Statin Treatment Intensity, Discontinuation, and Long-Term Outcome in Patients With Acute Myocardial Infarction and Impaired Kidney Function
Khedri, M., Szummer, K. E., Lundman, P., Jernberg, T., Desta, L., Lindahl, B., Erlinge, D., Jacobson, S. H., & Spaak, J. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001402 · Cited by 2
Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
Li, P., Chen, J., Li, N., You, X., Shen, L., & Zhou, N. (2023) · Cardiology Discovery · doi:10.1097/cd9.0000000000000092 · Cited by 2
Risco cardiovascular em hipertensos e diabéticos acompanhados em uma unidade básica de saúde
Cunha, L. C. C., França, A. K. T. D. C., dos Santos, M. S. B., & Santos, E. M. D. (2023) · Saúde e Pesquisa · doi:10.17765/2176-9206.2023v16n2.e11508 · Cited by 2
PENGGUNAAN STATIN DAN ANTIPLATELET SEBAGAI PENCEGAHAN SEKUNDER KOMPLIKASI KARDIOVASKULER PADA PASIEN DIABETES MELITUS TIPE 2
Ratnasari, P. M. D., Kurnianta, P. D. M., & Prasetya, A. A. N. P. R. (2020) · Majalah Farmasi dan Farmakologi · doi:10.20956/mff.v24i2.10384 · Cited by 2
Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study
Zhou, J., Chin, C. T., Huang, X., Guo, N., Wu, Y., Yu, B., Qiao, S., Chen, J., Han, Y., Ge, J., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.015 · Cited by 2
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations
Feldman, D. I., Michos, E. D., Stone, N. J., Gluckman, T. J., Cainzos‐Achirica, M., Virani, S. S., & Blumenthal, R. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100117 · Cited by 2

Authors: Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A.
Affiliations: Inova Health System (US)
University of Iowa (US)
Antoni Jurasz University Hospital (PL)
Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Cardiovascular Research Network
Università Cattolica del Sacro Cuore (IT)
Nicolaus Copernicus University (PL)
University of Alberta (CA)
Corresponding author: Robinson, Jennifer G.
ORCID: Navarese, Eliano P.
Robinson, Jennifer G.
Kowalewski, Mariusz
Andreotti, Felicita
Tantry, Udaya
Kubica, Jacek
Raggi, Paolo
Gurbel, Paul A.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2018-04-17
Volume: 319
Issue: 15
Pages: 1566
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2018.2525
PMC: PMC5933331
OpenAlex: W2800876320
Semantic Scholar: e998030b0bef031f54619a07cde9f01df4ce9807
Cited by: 549
References: 58
Citations by year: 2026: 36 · 2025: 74 · 2024: 81 · 2023: 70 · 2022: 56 · 2021: 76 · 2020: 62 · 2019: 68 · 2018: 26
FWCI: 12.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: LDL cholesterol, LDL cholesterol lowering, statins, ezetimibe, PCSK9 inhibitors, all-cause mortality, cardiovascular mortality, major adverse cardiac events, lipid-lowering therapy, dose-response relationship, treatment intensity, risk stratification, randomized controlled trials, meta-regression, risk of bias assessment, risk difference, relative risk, number needed to harm
MeSH terms: Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Mortality, Regression Analysis, Risk, Confounding Factors, Epidemiologic, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks